Table 5 Literature review detailing clinical outcomes of adjuvant post-operative therapy of oral tongue carcinoma. This study’s results (under Ianosvky et al) compares favorably with previously published reports
From: The role of brachytherapy for margin control in oral tongue squamous cell carcinoma
Paper | TNM | Patient number | Follow up, median (months) | Treatment | OS | DSS | DFS | Local control | Complications - Acute | Complications - Late |
|---|---|---|---|---|---|---|---|---|---|---|
Primary Surgery + Adjuvant BRTx for + ve or Close Margins | ||||||||||
Lapeyre et al 2004 [16] | T1–4, N0–3, M0a | 82 | 69 (mean) | BRTxb ± EBRTx | 68% (5 yr) | 80% (5 yr) | 81% (2 yr) | 43% Grade 1: 12 Grade 2: 17 Grade 3: 8 | ||
Ayukawa et al 2007 [10] | T1–2, N0, M0 | 28 | 72 | BRTxb | 96% (5 yr) | 92% (5 yr) | 8% Grade 1 + 2 | |||
Petera at al 2015 [13] | T1–3, N0, M0 | 30 | 40 (mean) | BRTx | 73% (3 yrs) | 65.4% (3 yrs) | 85.4% (3 yrs) | All Grade 2 | 1 ORN 2 Soft tissue necrosis | |
Goineau et al 2015 [9] | T1–2, N0–3c | 112 | 80.4 | BRTx ± EBRTx neck ± CTx | 72% (2 yrs) 56% (5 yrs) | 81% (2 yrs) 67% (5 yrs) | 79% (2 yrs) 76% (5 yrs) | All grade ≥ 2 mucositis 12% infection requiring ABx. | 22% grade ≥ 2 tongue necrosis requiring surgery. 8% pain requiring narcotics | |
Ianovski et al 2020 | T1–3,N0–3, M0 | 55 | 25.4 | BRTx ± EBRTx neck ± CTx | 75.6% (3 yrs) 59.1% (5 yrs) | 82.3% (3 yrs) 68.6% (5 yrs) | 74.3% (3 yrs) | 86.3% (3 yrs) | 1 haemorrhage (Grade 4) | 5% grade 2 pain requiring narcotics |
Primary BRTx ± ND ± EBRTx ± CTx ± Intralesional CTxd | ||||||||||
Urashima et al 2007 [17] | T1–2, N0, M0 | 409 | BRTx ± EBRTx ± CTx ± intralesional | 72.2–82.3% (5 yrs) | 56–64.6% (5 yrs) | 86–97% (5 yrs) | 19.8% ulcer, 6.6% ORN | |||
Bhalavat et al 2009 [14] | T1–2, N0, M0 | 57 | 64 | BRTx ± EBRTx | 67% (5 yrs) | 51% (5 yrs) | 59.7% (5 yrs) | BRTx: 47% grade III mucositis. 1 haemorrhage BRTx + EBRTx: 60% grade II, 10% grade III mucositis + skin toxicity | 14% submental fibrosis 12.3% soft tissue necrosis 2 ORN | |
Akiyama et al 2012 [18] | T1–2, N0, M0 | 51 | 45 | BRTx | 88% (2 yrs) | 88% (2 yrs) | 9% soft tissue ulcers 9% bone exposure | |||
Matsumoto et al 2013 [19] | T1–2, N0, M0 | 67 | 58.6 | BRTx ± EBRTx ± CTx ± intralesional | 88.7% (5 yrs) | 92.1% (5 yrs) | 76% (5 yrs) | 94% (5 yrs) | 15% grade 3 + 7% grade 2mucositis | |
Bansal et al 2016 [20] | T1–2, N0, M0 | 62 | 53.5 | BRTx ± EBRTx/ND to neck | 78.8% (5 yrs) | 59.3% (5 yrs) | 68.2% (5 yrs) | 32.9%: pain +trismus 4.3%, ankyloglossia 7.6%, ORN 1.1%, induration 13.1% | ||
Primary Surgery ± EBRTx ± CTx | ||||||||||
Ling et al 2013 [21] | T1–4, N0–3 | 210 | 36.6 | Sx +/− EBRTx +/− CTx | 44.4% (5 yr) | 47.7% (5 yr) | ||||
Okuyemi et al 2014 [22] | T0–4, N0–3 | 166 | Sx +/− EBRTx +/−? CTx | 70.4% (2 yrs) 57.7% (5 yrs) | 84.1% (2 yrs) 78% (5 yrs) | |||||
Mroueh et al 2017 [23] | T1–4, N0–3 | 325 | 43 (mean) | Sx +/− EBRTx +/− CTx | 61% (5 yrs) | 76% (5 yrs) | 65% (5 yrs) | |||
Liao et all 2017 [24] | T1–4, N0–3 | 8509 | Sx +/− RTx +/− CTx | 69% (5 yr) | 77% (5 yr) | |||||
Zhang et al 2017 [25] | T1–4, N0–3 | 457 | 39 | Sx +/− RTx +/− CTx | 68–74.6% (3 yr) 33.1–64.8% (5 yr)α | |||||